Literature DB >> 8317909

Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal.

M González Barón1, J Feliu, A Ordoñez, A Colmenarejo, E Espinosa, P Zamora, I de la Gandara, J I Jalon.   

Abstract

Twenty-six patients with advanced colorectal cancer were treated with UFT and leucovorin (LV). On day 1, patients received LV 500 mg/m2 in IV infusion, followed by 15 mg/12 h for 13 days. On days 1 to 14, patients took oral UFT twice daily. Three cycles were given every 28 days, unless grade III-IV toxicity appeared. The initial dose of UFT (200 mg/day) was increased until 800 mg/day. Dose limiting toxicities were stomatitis, diarrhea and epigastralgia. The maximum tolerated dose of UFT was 390 +/- 10 mg/m2. Three out of 24 evaluable patients achieved a partial response and 1 a complete response with UFT doses of 260 to 390 mg/m2. These results warrant confirmation in phase II studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8317909

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Oncopaz cooperative group.

Authors:  Manuel González Barón; Enrique Espinosa
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

Review 2.  Oral tegafur/uracil.

Authors:  K Wellington; K L Goa
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.

Authors:  P M Hoff
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

4.  Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.

Authors:  J Feliu; J M Vicent; C García-Girón; M Constela; E Fonseca; J Aparicio; M Lomas; L Antón-Aparicio; F J Dorta; M Gonzalez-Baron
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.